CD3G
Overview
CD3G encodes the CD3 gamma chain, a component of the T-cell receptor (TCR)-associated CD3 signaling complex. CD3G, together with CD3D, CD3E, and CD247 (CD3 zeta), is required for proper TCR-CD3 complex assembly, surface expression, and signal transduction. CD3G expression in tumor tissue reflects the presence and activation state of infiltrating T lymphocytes.
Alterations observed in the corpus
- CD3G was identified as a component of the TCR/co-stimulatory immunological synapse upregulated on-therapy (cycle 1 day 29) in melanoma patients receiving nivolumab (anti-PD-1), as part of a 695-gene DEG set enriched in the genomic-contraction phenotype (q < 0.10) and a broader 475-DEG pharmacologic on-therapy response set (q < 0.20), encompassing PD-1 signaling, CD28 co-stimulation, downstream TCR signaling, IFN-gamma, and IL-2 signaling. PMID:29033130
Cancer types (linked)
- SKCM: CD3G on-therapy upregulation is part of a coordinated T-cell activation transcriptional program observed in melanoma patients on nivolumab. The contraction-phenotype DEG set, including CD3G, stratified survival in independent immunotherapy cohorts. PMID:29033130
Co-occurrence and mutual exclusivity
Therapeutic relevance
- Coordinated on-therapy induction of CD3G as part of the TCR complex gene program supports the mechanistic model that anti-PD-1 therapy (nivolumab) restores productive T-cell activation in the tumor microenvironment. PMID:29033130
Open questions
- Pre-therapy CD3G expression as an independent predictive biomarker for anti-PD-1 response was not specifically reported in this study. PMID:29033130
Sources
This page was processed by crosslinker on 2026-05-15.